Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
15.9.2022 17:00:00 EEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini- CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
Contact information
For further information:
Caravan Biologix, Inc.:
Jeff Riley
CEO
+1.917.510.3773
jeff@caravanbio.com
MDimune Inc.
Seung Wook Oh, Ph.D.:
CSO
+82-2-2655-2636
swoh@mdimune.com; Info@biodroneus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress12.5.2026 16:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. “The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “These presentations include findings from the frontMIND study, which support the U.S. and EU regulatory applications for tafasitamab (Monjuvi®/Minjuvi®) in patients with first-line diffuse large B-cell lymphoma (DLBCL). Additionally, data presentations for INCA033989, which support our Phase 3 trials, demonstrate the steady advancement of this molecularly targeted therapy that has the potential to revolutionize
Lenovo Enables One-Week Deployment of Production-Ready Agentic AI to Transform Enterprise Workflows12.5.2026 16:00:00 EEST | Press release
Lenovo is enabling enterprises to deploy production-ready, agentic AI solutions in as little as one week1, eliminating the long development cycles that typically delay AI from reaching production, while maintaining enterprise-grade security, governance, and control. This is not theoretical, independent analysis from Signal65 confirms these results in real-world deployments. Lenovo’s Knowledge Super Agent reduced time spent on knowledge-related tasks by 30%, saving up to 120 hours per employee annually. In multiple deployments, organizations reached production up to 24× faster than with custom-built approaches, demonstrating how faster, secure deployment translates directly into faster business outcomes. These results reflect faster deployment and more efficient AI utilization, where each interaction delivers measurable business value. Delivered through the Lenovo AI Library as part of Lenovo Hybrid AI Advantage™, this approach allows organizations to move directly from pilot to operati
Nikkiso Signs Agreement With Maran Tankers Management to Provide Aftermarket Service Support12.5.2026 16:00:00 EEST | Press release
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) has announced today that it has signed a long-term service agreement with oil tanker shipping firm Maran Tankers Management Inc. Under the five-year agreement, Nikkiso CE&IG will deliver comprehensive global aftermarket support for Maran Tankers’ high pressure pumps, including scheduled cold end valve repairs at defined intervals. To guarantee minimal turnaround time, Nikkiso CE&IG will maintain critical inventory across its Marine Hubs worldwide, enabling cold ends to be received by vessels within days rather than the industry’s average of months. Nikkiso CE&IG will also provide technical guidance to Maran Tankers and carry out extended overhauls during scheduled dry-docking periods. Sean Fanniff, President of Nikkiso CE&IG’s Cryogenic Services Business Unit, said: “With Marine Hubs across Southeast Asia, Europe, the Middle East, the US, and China, we can provide our clients with a coordinated global approach and seamless p
Introducing Cognite Flows™: The First Fully Integrated, AI-Native Industrial Experience that Accelerates Customer Value12.5.2026 16:00:00 EEST | Press release
Cognite, the global leader in Industrial AI, today announced Cognite Flows™, a new standard for industrial experiences that fundamentally redefines how teams engage with AI, apps, and data to address operational challenges. Designed to optimize the daily workflows of frontline teams, Cognite Flows puts everything they need—AI-driven insights and real-time data from multiple apps across every corner of the company—into an easily customized, single-screen workspace. For the first time in an industrial setting, software will adapt to the user, rather than the user needing to adapt to the software. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512315975/en/ Introducing Cognite Flows™: The First Fully Integrated, AI-Native Industrial Experience that Accelerates Customer Value Cognite Flows is the action layer of the Cognite platform, empowering teams to build, scale, and use production-ready workflows 100x faster through adap
Mixpanel Introduces Mixpanel AI, Delivering Always-On Product Intelligence12.5.2026 16:00:00 EEST | Press release
Mixpanel, a global leader in product intelligence and analytics, today introduced Mixpanel AI — the always-on product intelligence system that helps teams ship faster and smarter by understanding how people use their products and what to do next. Unlike query-based analytics assistants, Mixpanel AI monitors your product continuously and surfaces insights and issues before teams think to ask, combining specialized AI agents, a business-aware Context Engine, and native integrations with the tools teams already use. Built on 17 years of product analytics infrastructure and trusted by more than 29,000 customers, Mixpanel AI turns product data into proactive, explainable intelligence that teams can act on — with the business context to make every answer relevant and the verified data foundation to make every answer trustworthy. “At Mixpanel we’re building autonomous product intelligence — always on to match the continuous pace of shipping today, and intelligent because it understands the co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom